Topics

Latest "approves first biosimilar Roche cancer drug Rituxan https" News Stories

16:40 EDT 17th October 2019 | BioPortfolio

Here are the most relevant search results for "approves first biosimilar Roche cancer drug Rituxan https" found in our extensive news archives from over 250 global news sources.

More Information about approves first biosimilar Roche cancer drug Rituxan https on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about approves first biosimilar Roche cancer drug Rituxan https for you to read. Along with our medical data and news we also list approves first biosimilar Roche cancer drug Rituxan https Clinical Trials, which are updated daily. BioPortfolio also has a large database of approves first biosimilar Roche cancer drug Rituxan https Companies for you to search.

Showing "approves first biosimilar Roche cancer drug Rituxan https" News Articles 1–25 of 36,000+

Thursday 17th October 2019

Immunomic Therapeutics to Present at Precision Lung Cancer World R&D Summit

Discussion of UNITE platform as applied in cancer immunotherapy Immunomic Therapeutics, Inc. announced today a presentation at the Precision Lung Cancer World R&D Summit in Boston. On Tuesday, October 22, Business Development Advisor at Immunomic, Yan Su, will present a talk entitled “Current & Future Application of the UNITE Platform in Cancer Immunotherapy,” highlighting Immunomic...


2019 Contrast Induced Nephropathy Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Contrast Induced Nephropathy Clinical Trials Study provides complete list of trials completed, ongoing and planned for Contrast Induced Nephropathy. It presents indepth analysis of Contrast Induced Nephropathy clinical trials across markets and companies. The research work is for providing complete understanding into trends in Contrast Induced Nephropathy. Th...

SureClinical and Clinilabs Announce Global Lunch & Learn Series for Clinical Operations

“Turbocharge Your Clinical Trials” Series Demonstrates Real-World Benefits of Going Digital NEW YORK (PRWEB) October 17, 2019 SureClinical, a global provider of innovative cloud solutions for the health sciences market and Clinilabs Drug Development Corporation, a CNS-focused contract research organization, are sponsoring a global Lunch & Learn series demonstrating how sponsors can stream...


Citizens Against Government Waste Names Speaker Nancy Pelosi October 2019 Porker of the Month

Today, Citizens Against Government Waste (CAGW) named Speaker Nancy Pelosi (D-Calif.) October 2019 Porker of the Month for pushing a partisan drug pricing bill that will implement dangerous price controls. Speaker Pelosi claims H.R. 3, her Lower Drug Cost

KHN’s ‘What The Health?’: Democrats Do Drugs (Prices)

House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to di...

Ipsen acquires Blueprint drug and moves further into ultra-rare disease - http://bit.ly/2MojPk0 pic.twitter.com/cI70heIVQL

Ipsen acquires Blueprint drug and moves further into ultra-rare disease - http://bit.ly/2MojPk0  pic.twitter.com/cI70heIVQL

Credence MedSystems secures grant for dual-chamber drug delivery device

Credence MedSystems has secured a grant from the Bill & Melinda Gates Foundation to develop its dual-chamber drug delivery device for the global health setting. The funding will The post Credence MedSystems secures grant for dual-chamber drug delivery device appeared first on NS Medical Devices.

Fidmi Medical secures US FDA approval for low-profile feeding tube system

Fidmi Medical, a portfolio company of The Trendlines Group, announced that the US Food and Drug Administration (FDA) has granted 510(K) approval for its low-profile enteral feeding device. The post Fidmi Medical secures US FDA approval for low-profile feeding tube system appeared first on NS Medical Devices.

Cleveland Diagnostics gets FDA breakthrough device status for prostate cancer diagnostic test

The data from multicentre prospective clinical trials demonstrated that the non-invasive, blood-based IsoPSA assay has significant superior diagnostic accuracy compared to traditional prostate-specific antigen (PSA) tests in detecting The post Cleveland Diagnostics gets FDA breakthrough device status for prostate cancer diagnostic test appeared first on NS Medical Devices.

Rep. Elijah Cummings, a longtime advocate for lower drug prices, passed away Thursday. Now Nancy Pelosi is naming Democrats’ drug pricing bill in his honor. https://buff.ly/2IZwaJd 

Rep. Elijah Cummings, a longtime advocate for lower drug prices, passed away Thursday. Now Nancy Pelosi is naming Democrats’ drug pricing bill in his honor. https://buff.ly/2IZwaJd 

Lilly's pegilodecakin combo falls at Phase 3 in pancreatic cancer: http://bit.ly/2nUr0qP  #pharma #cancer #PancreaticCancerpic.twitter.com/1ckjZh121D

Lilly's pegilodecakin combo falls at Phase 3 in pancreatic cancer: http://bit.ly/2nUr0qP  #pharma #cancer #PancreaticCancer pic.twitter.com/1ckjZh121D

Carving out a research niche in early detection: Charlie Massie, Career Development Fellow

Research Feature Dr Charlie Massie is a Junior Group Leader in the Early Detection Programme at the Cancer Research UK (CRUK) Cambridge Centre and a CRUK Career Development Fellowship (CDF) holder. He is using his bioinformatics and cancer genomics experience to develop tests that will dis

Chemotherapy Triplet Elicits Encouraging Activity in Pancreatic Adenocarcinoma

The addition of cisplatin to gemcitabine and nab-paclitaxel resulted in encouraging activity in patients with previously untreated advanced pancreatic cancer, despite not having demonstrated the prespecified number of complete responses to meet the primary endpoint of a phase Ib/II clinical trial (NCT01893801), according to findings published in JAMA Oncology.

AstraZeneca receives FDA Priority Review for breast cancer drug: http://bit.ly/2OTNPG1  #Cancerpic.twitter.com/tkOfj2Qg6n

AstraZeneca receives FDA Priority Review for breast cancer drug: http://bit.ly/2OTNPG1  #Cancer pic.twitter.com/tkOfj2Qg6n

2019 Squamous NonSmall Cell Lung Cancer Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Squamous NonSmall Cell Lung Cancer Clinical Trials Study provides complete list of trials completed, ongoing and planned for Squamous NonSmall Cell Lung Cancer. It presents indepth analysis of Squamous NonSmall Cell Lung Cancer clinical trials across markets and companies. The research work is for providing complete understanding into trends in Squamous NonSm...

Roche: Angriff auf Allzeithoch vertagt

Kulmbach (www.aktiencheck.de) - Roche-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des Pharmagiganten Roche A...

The journey to improving Rwanda’s cancer referral system is no short trip. But with the help of @BIOVentures and everyone involved in this mission, Nan Wang and his team can use their combined expertise to help take the initial steps. #InventingForLife

The journey to improving Rwanda’s cancer referral system is no short trip. But with the help of @BIOVentures and everyone involved in this mission, Nan Wang and his team can use their combined expertise to help take the initial steps. #InventingForLife #FellowInventors pic.twitter.com/KmC5UkFnij

Credit Suisse hebt Ziel für Roche auf 315 Franken - 'Neutral'

Die Schweizer Bank Credit Suisse hat das Kursziel für Roche nach Umsatzzahlen zum dritten Quartal von 300 auf 315 Franken angehoben und die Einstufung auf "Neutral" belassen. Die Resultate zeugten...

Consultant who put risperidone in wife’s tea without her knowledge is suspended for three months

A locum consultant who told his wife’s GP that he had been slipping the antipsychotic drug risperidone covertly into her tea—and who asked the GP for more risperidone so that he could continue doing...

Onxeo, Winner of the Innov'up Leader PIA Call for Projects, Receives Funding of €495,000

The winning project aims to develop a drug candidate in immuno-oncology from the platON platform Funding from the French State and the Île-de-France Region, operated by Bpifrance, consists of a gr...

4th Annual 2019 Global CESI-MS Symposium Highlights SCIEX Technology

Event features research and new capabilities in biopharmaceuticals, proteomics, metabolomics, and industrial research SCIEX, a global leader in life science analytical technologies, has announced that the 2019

PACIFIC Trial Paves Way for More Immunotherapy Advances in Stage III NSCLC

Anna Chalmers, MD, discusses the PACIFIC trial and how its impact continues to change the treatment paradigm in stage III non-small cell lung cancer. 

Plexium Debuts With $28M and a New Take on Protein Degradation Drugs

Even as researchers discover more links between specific proteins and human disease, it’s still hard to find small molecules or antibodies that can bind to those drug targets. San Diego biotech Plexium is the latest addition to the growing number of startups aiming to use technology to devise new drugs that can target those currently […]

Roche erhält in USA Zulassung für Grippemittel Xofluza bei Hochrisikopatienten

San Francisco (awp) - Der Pharmakonzern Roche hat von der US-Gesundheitsbehörde FDA die Zulassung für sein Grippemittel Xofluza bei Patienten mit hohem Komplikationsrisiko erhalten. Mit der nahende...

AZ’s ADC receives priority review

US FDA provides AZ and Daiichi Sankyoâs ADC for the treatment of metastatic breast cancer priority review, with a decision set for Q2 2020.


Quick Search

News Quicklinks